meg terrell has more on this big day in biotech, what is behind the numbers at puma and bio again and what investors can look forward to. >> reporter: stocks are known for versatility, big risk, big reward. puma soared on the drug for breast cancer. in a trial of more than 2,000 patients the medicine helps people live for 33% longer without disease professing. the drug was tested for a specific genetic mutation. it will apply for approval in the first half of next year. it would bring in $4 billion according to estimates. the results may also make puma a likely acquisition target analysts said. the ceo is known for deal making. he sold the last company, couger biotech to johnson & johnson for a billion dollars in 2009 and a blowout day for the company that topped estimates for second quarter results and raise the full year guidance for the ms drug. >> we had a great quarter, revenues are up 40% and eps up 52% versus q 2 of last year and really driven by the base ms business, our new oral drug has continued to perform well in the u.s. it's been launched in europe now. >> bio again rece

for "nightly business report", i'm meg terrell. >>> a big earning's miss for ups. higher spending and increased cost caused them to lower cost for the year and that sent shares down by 4%. morgan brennan takes a closer look. >> reporter: the world's largest package delivery company shipped 7% more packages around the globe than a year ago. shipping activity surged internationally especially in europe but here in the u.s., more consumers purchase products online. e commerce fueled a 60% increase in upss less expensive shipments. positive sign for consumer spending, but a drag on the delivery giants revenue per package. >> it is an interesting time. we're seeing actually the strongest growth in our domestic business that we've seen in over a decade. e commerce is driving it but we have investments to expand capacity and handle the growth. that's why we're seeing mixed results economically but great results as far as demand. >> reporter: those investments are in response to botched holiday season delivers after competitors couldn't keep pace with the last-minute surge

for "nightly business report", i'm meg terrell. >>> shares of abbvie and shire rose today. abbvie up 2.5%. >>> our market monitor has a list of stocks he says could double in price over the next 12 to 18 months and he's going to share them with us, next. >>> the calendar says july, school was just out a few weeks ago but retailers are already gearing up for back to school sales and just today the national retail federation predicted parents will spend nearly $8.5 billion this year on tablets and other electronic devices for their kids. that's about 7% more than they spent one year ago. >>> fedex says it will fight charges it helped internet pharmacies distribute drugs illegally. a federal grand jury in san francisco yesterday returned a 15-count indictment against the delivery giant saying senior management at fedex knew what was going on. it's yet another glimpse into the shadow world of internet drugstores. >> reporter: in california, dan is mourning the death of his wife cheryl. >> there isn't a day that goes by that i don't think of her and miss her. >> reporter: cheryl

our reporter meg terrell is fresh off the conference call to react to all of this and the earnings. at's right. today allergan reported second quarter roults that beat both on earnings and on sales. also announced a restructuring which people had been anticipating, cutting about 13% of its work force or 1500 workers to save about $475 million annually. on that conference call, a lot of questions about what the company's going to do with its cash. the ceo saying the number one request from shareholders has been to make an acquisition of its own. so they may look at acquisitions that could help them cut their tax bill. the number one priority there is so find a company that that would add to earnings. looking to that. also news out of valiant saying they've contacted regulators in both canada and the united states about what they say are false and misleading claims that allergan's been making about valiant's company and its stock. so that's the news today. a lot of back-and-forth. this has been a three-month-long ordeal. it continues to keep going. back to you. >> allergan, valiant, ju

for "nightly business report", i'm meg terrell. >> to read more about nash and how drugs to treat the disease could rival hepatitis c medications go to nbr.com. >>> another piece of medical news to tell you about which could be big news. the swiss drug maker is teaming up with google to develop a smart contact lens that measures blood glucose in tear data. the smart lens may help restore the eye's ability to focus. amazing. >>> coming up next, the new space race with a billion dollars in taxpayer money committed and a dow component vying to win. why the spacecraft competition has a lot riding on it. >>> stocks might be flirting with historic ty highs but a different story for energy prices. crude soared, the first time in more than two months and gasoline prices have fallen for 18 days in a row with gasbuddy.com reporting today that the average price fell below $3.66 for the first time in three months. >> there is a space race heating up. nasa has to choose a manufact e manufacturer for a crew carrier and the stakes are high for the private companies and for one large publicly traded

meg terrell is live in the news room. plenty of deals here, meg. >> we're looking at $19.5 billion. that's the estimated loss if aversion deals continue. inversions are setting a record pace, nine deals have already been agreed to this year by companies including medtronic and chiquita brands. overseas cash piling are growing and now estimated to be about $1 trillion. companies don't want to bring that money back to the united states and face a 35% corporate tax rate here. u.s. ceos have increasingly been calling for changes. >> the current u.s. tax system puts u.s. companies at a disadvantage relative to ous competitors. that's a simple fact. i think some of the companies acting on these inversions and doing these inversions are simply trying to level the playing field. if we've got a concern about inversions, we need to tackle our tax code. >> on the flip side, fear that washington will act to top inversions has helped accelerate m&a. the new proposals are already on the table. already, though, since 1983, an estimated 76 companies have left the u.s. for greener tax pastures. tyle

and cnbc pharmaceutical reporter meg terrell is also here.ad a bunch -- i didn't make that up. i guess you got a twitter account that says it's your hair and everything else. >> there's a twitter account called ron cohen's hair. we actually tweet lighthearted comments about hair -- >> i have -- >> you guys created? it's not somebody else. >> no, we created it on april fools' day because there's a very notable analyst in the biotech industry, he's got 90,000 followers, and he constantly talks about my hair in his notes about the company, and the industry. >> unfortunately, many people on tv know we can't escape -- there are things that are all about the hair. and steve to this day, you still go to baldaholics anonymous. >> it's not a disease. it's not a handicap. >> it's like an affliction. >> it's not -- it's okay. ask wilbur. wilbur is smart, and he's -- he has no hair. >> listen to you, you're yelling. >> is big hair therapeutically sound? >> i'm glad we're getting down to a serious biotechnology talk. i think that's going to take more time

meg terrell puts a new study under the microscope showing how brain activity differs between high and low earners on wall street. fascinating stuff, and the results may surprise you. but actual traders who will learn about this study at the same time as the rest of us, and they will join us, coming up. and we will debrief their brains when we come back in a moment. stay tuned. in a world that's changing faster than ever, we believe outshining the competition tomorrow requires challenging your business inside and out today. at cognizant, we help forward-looking companies run better and run different - to give your customers every reason to keep looking for you. so if you're ready to see opportunities and see them through, we say: let's get to work. because the future belongs to those who challenge the present. [ girl ] my mom, she makes underwater fans that are powered by the moon. ♪ she can print amazing things, right from her computer. [ whirring ] [ train whistle blows ] she makes trains that are friends with trees. ♪ my mom works at ge. ♪ yeah, citi mobile. pay the dog sitter? my m

. >>> to guy with the alzheimer's epidemic, meg terrell joins us now with more. i mean companies don't always do things for altruistic reasons. that's not the only reason. >> they usually don't. >> that doesn't mean that this isn't going to get handled. because this -- anyone that figures something out with alzheimer's is going to make a lot of money and help a lot of people. >> absolutely. this is a double whammy doing well by doing good. >> think how many people that we're talking about. and you look at what it might cost a year you're talking about $10 billion, $20 billion in drugs. >> i was thinking about that this morning. two years ago, three years ago when there were a couple of trials going on the estimates for what these drugs could bring in was about $5 billion. now you see drugs for hepatitis-c getting up to $11 million a year. >> that's an epidemic but it's not like this is an epidemic. >> something like alzheimer's you can imagine it would be huge. >> would affect how many people? >> what are the numbers? >> how many people -- we've got 5 million peo